View ValuationCovalon Technologies 향후 성장Future 기준 점검 3/6Covalon Technologies (는) 각각 연간 24.8% 및 8.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 23.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12% 로 예상됩니다.핵심 정보24.8%이익 성장률23.78%EPS 성장률Biotechs 이익 성장25.3%매출 성장률8.7%향후 자기자본이익률12.00%애널리스트 커버리지Low마지막 업데이트21 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 10Covalon Technologies Ltd. Announces the Appointment of Murray Miller to Its Board of Directors as an Independent DirectorCovalon Technologies Ltd. announced the appointment of Dr. Murray Miller to its Board of Directors (Board) as an independent director subject to TSX Venture Exchange approval. Dr. Miller graduated as a Medical Doctor from the University of Manitoba in 1982. He completed his residency in Radiology at the University of Toronto. Dr. Miller has served as a physician and practice leader at Ontario hospitals and community clinics since then. Dr. Miller has held leadership positions in medical associations and has served as an advisor to a number of biotech and medical technology companies. In connection with the appointment of Dr. Miller to the Board, the Company has granted to Dr. Miller an aggregate of 22,222 Deferred Share Units (DSUs) for all of Dr. Millers annual directors fees for fiscal year 2026 as opposed to cash. The DSUs were granted under the Companys Amended and Restated Omnibus Long-Term Incentive Plan (the LTIP) adopted effective on March 25, 2026. The DSUs will vest 12 months from the date of grant.공시 • May 15Covalon Technologies Ltd. to Report Q2, 2026 Results on May 21, 2026Covalon Technologies Ltd. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on May 21, 2026공시 • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026공시 • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.공시 • Dec 04Covalon Technologies Ltd. to Report Q4, 2025 Results on Dec 11, 2025Covalon Technologies Ltd. announced that they will report Q4, 2025 results Pre-Market on Dec 11, 2025공시 • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).공시 • Sep 26Covalon Technologies Ltd. Presents Evidence-Backed Innovations Making A Difference for Critically Ill Children At AphonCovalon Technologies Ltd. presented evidence-backed innovations making a difference for critically ill Children At Aphon. The company announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference, September 25-27, 2025 in Providence, Rhode Island. The annual conference, attended by more than 800 nurse leaders from across the United States and around the world, is recognized as the premier educational experience for pediatric hematology/oncology nurses, bringing together clinicians and industry experts to advance knowledge, share research, and improve patient outcomes. Last week, the Journal of the Association for Vascular Access (JAVA) published peer-reviewed data from the Children's Hospital at Montefiore describing how the hospital's experience with VALGuard®? Line Guard was associated with positive outcomes, including a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024, and a sustained period of zero CLABSI's (Central Line Associated Blood Stream Infections) in the Pediatric Critical Care Unit. The publication provides peer-reviewed evidence on VALGuard®? and highlight its role in protecting vulnerable pediatric patients. In addition, new economic findings from a U.S. hospital study demonstrated that CovaClear®? silicone dressing, used as a cover for primary dressings, greatly helped reduce unplanned dressing changes caused by soiling, leaks, or contamination. Avoiding unplanned dressing changes translates into measurable cost savings for hospitals and reduced workload for nurses, while preserving skin integrity for patients who already face intensive therapies. These findings underscore the dual impact of Covalon's portfolio which is designed to improve patient outcomes while creating measurable efficiencies for hospitals seeking to optimize both quality of care and economic performance. At APHON, Covalon will showcase the breadth of its vascular access portfolio, including: VALGuard®? Line Guard - A transparent, single-use barrier designed to cover and protect IV line connections and catheter hubs from external contaminants, including body fluids and secretions that can lead to infection. VALGuard®? incorporates a unique quick-release pull strip that enables fast access to the line for clinicians. CovaClear®? Dressings - A family of versatile gentle-to-skin silicone dressings that can be used as a primary IV securement dressing or as a protective cover over existing primary dressings. By helping reduce unplanned primary IV dressing changes caused by soiled, fluid leaks, or external contamination, CovaClear®? helps customers save money on wasted supplies, reduce nursing workload, and supports efforts to preserve patient skin integrity. IV Clear®? Dressings - Afamily of transparent IV securement dressings that combine gentle-to-skin silicone adhesive technology with edge-to-edge coverage of chlorhexidine and silver for antimicrobial protection. IV Clear®? provides complete transparency to the insertion site, supporting routine assessment and better line management. The company's solutions are designed not only to support better outcomes for patients but also to provide hospitals with measurable savings and long-term value.공시 • Sep 24Covalon Technologies Ltd. Announces Board ChangesCovalon Technologies Ltd. announced that Mr. Abe Schwartz has been elected Chair of the Board of the Company. Mr. Schwartz succeeds Mr. Amir Boloor, who has decided to step down as a director and Executive Chair of Covalon with effect September 23, 2025. Mr. Schwartz, a member of the Covalon Board since 2008, has previously served as Covalon Board Chair from 2012 until 2020. He has been a successful Healthcare and I.T. industry entrepreneur, CEO and investor over the past 50 years and is Covalon’s largest shareholder.공시 • Aug 14Covalon Technologies Ltd. to Report Q3, 2025 Results on Aug 21, 2025Covalon Technologies Ltd. announced that they will report Q3, 2025 results Pre-Market on Aug 21, 2025공시 • May 27Covalon Technologies Ltd. Announces New Clinical Research Evaluating Vascular Access Line GuardCovalon Technologies Ltd. announced that exciting results from a clinical study evaluating the use of its VALGuard Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall - September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world.공시 • May 21Covalon Technologies Ltd. to Report Q2, 2025 Results on May 28, 2025Covalon Technologies Ltd. announced that they will report Q2, 2025 results Pre-Market on May 28, 2025공시 • Feb 14Covalon Technologies Ltd. to Report Q1, 2025 Results on Feb 21, 2025Covalon Technologies Ltd. announced that they will report Q1, 2025 results Pre-Market on Feb 21, 2025공시 • Jan 06Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025.공시 • Dec 19Covalon Technologies Ltd. to Report Q4, 2024 Results on Jan 07, 2025Covalon Technologies Ltd. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Jan 07, 2025공시 • Aug 14Covalon Technologies Ltd. to Report Q3, 2024 Results on Aug 21, 2024Covalon Technologies Ltd. announced that they will report Q3, 2024 results Pre-Market on Aug 21, 2024공시 • May 24Covalon Technologies Ltd. to Report Q2, 2024 Results on May 29, 2024Covalon Technologies Ltd. announced that they will report Q2, 2024 results Pre-Market on May 29, 2024공시 • Jan 26+ 1 more updateCovalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - OperationsCovalon Technologies Ltd. announced that Ms. Kim Crooks has rejoined Covalon as the Senior Vice President - Operations. In this new role, Ms. Crooks is responsible for overseeing the direction, planning, and execution of Manufacturing, Quality Assurance and Quality Control, Regulatory Affairs, and Human Resources. Ms. Crooks was previously Vice President of Operations at Covalon from 2012 to 2022.공시 • Dec 21Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024.공시 • Oct 12Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in ChicagoCovalon Technologies Ltd. announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference. Scheduled from October 12 to October 14, 2023, in Chicago, this conference is the largest conference for nurse professionals. All attendees are invited to booth 1835 at the McCormick Place Convention Center, where they can experience first-hand, innovative compassionate care solutions designed to elevate patient care standards and nursing excellence. Covalon's patented infection prevention and wound care products include: VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.공시 • Sep 28Covalon Technologies Ltd. Announces Chief Executive Officer ChangesCovalon Technologies Ltd. appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer, effective immediately following the departure of Brian Pedlar. The Board has commenced a search for a permanent CEO. Mr. Boloor succeeds Brian Pedlar, who will remain on Covalon’s Board of Directors.공시 • Sep 27Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent DirectorCovalon Technologies Ltd. appointed Joseph Cordiano to serve as lead independent director.공시 • Aug 15Covalon Technologies Ltd. to Report Q3, 2023 Results on Aug 16, 2023Covalon Technologies Ltd. announced that they will report Q3, 2023 results Pre-Market on Aug 16, 2023공시 • May 24Covalon Technologies Ltd. to Report Q2, 2023 Results on May 25, 2023Covalon Technologies Ltd. announced that they will report Q2, 2023 results Pre-Market on May 25, 2023공시 • Feb 18Covalon Technologies Ltd. to Report Q1, 2023 Results on Feb 23, 2023Covalon Technologies Ltd. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 23, 2023공시 • Jan 24Covalon Technologies Ltd. to Report Q4, 2022 Results on Jan 25, 2023Covalon Technologies Ltd. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 25, 2023이익 및 매출 성장 예측OTCPK:CVAL.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/2028435N/A519/30/2027404N/A419/30/2026353N/A613/31/202633256N/A12/31/202532178N/A9/30/202533212N/A6/30/202533245N/A3/31/202534455N/A12/31/202435534N/A9/30/202431333N/A6/30/202429-111N/A3/31/202426-3-3-2N/A12/31/202325-5-4-3N/A9/30/202327-4-5-3N/A6/30/202325-6-6-5N/A3/31/202323-7-9-8N/A12/31/202219-9-10-8N/A9/30/202218-9-9-8N/A6/30/202219-4-8-8N/A3/31/202221-2-4-3N/A12/31/202122000N/A9/30/202120000N/A6/30/20217-411N/A3/31/20217-411N/A12/31/20208-800N/A9/30/202014-8-4-4N/A6/30/202026-8-3-3N/A3/31/202027-12-4-4N/A12/31/201935-8N/A-4N/A9/30/201934-9N/A-3N/A6/30/201934-6N/A-2N/A3/31/201935-1N/A-2N/A12/31/201828-1N/A-4N/A9/30/2018272N/A-1N/A6/30/2018303N/A-1N/A3/31/2018281N/A-1N/A12/31/2017282N/A0N/A9/30/2017272N/A0N/A6/30/201718-1N/A-2N/A3/31/201715-1N/A-1N/A12/31/201610-3N/A-1N/A9/30/20167-3N/A-1N/A6/30/20168-2N/A-3N/A3/31/20167-2N/A-3N/A12/31/201590N/A-3N/A9/30/20158-1N/A-2N/A6/30/20157-1N/A-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CVAL.F 의 연간 예상 수익 증가율(24.8%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: CVAL.F 의 연간 수익(24.8%)이 US 시장(18.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: CVAL.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: CVAL.F 의 수익(연간 8.7%)이 US 시장(연간 12.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: CVAL.F 의 수익(연간 8.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CVAL.F의 자본 수익률은 3년 후 12%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/26 17:31종가2026/06/24 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Covalon Technologies Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andre UddinResearch Capital Corporation
공시 • Jun 10Covalon Technologies Ltd. Announces the Appointment of Murray Miller to Its Board of Directors as an Independent DirectorCovalon Technologies Ltd. announced the appointment of Dr. Murray Miller to its Board of Directors (Board) as an independent director subject to TSX Venture Exchange approval. Dr. Miller graduated as a Medical Doctor from the University of Manitoba in 1982. He completed his residency in Radiology at the University of Toronto. Dr. Miller has served as a physician and practice leader at Ontario hospitals and community clinics since then. Dr. Miller has held leadership positions in medical associations and has served as an advisor to a number of biotech and medical technology companies. In connection with the appointment of Dr. Miller to the Board, the Company has granted to Dr. Miller an aggregate of 22,222 Deferred Share Units (DSUs) for all of Dr. Millers annual directors fees for fiscal year 2026 as opposed to cash. The DSUs were granted under the Companys Amended and Restated Omnibus Long-Term Incentive Plan (the LTIP) adopted effective on March 25, 2026. The DSUs will vest 12 months from the date of grant.
공시 • May 15Covalon Technologies Ltd. to Report Q2, 2026 Results on May 21, 2026Covalon Technologies Ltd. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on May 21, 2026
공시 • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026
공시 • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.
공시 • Dec 04Covalon Technologies Ltd. to Report Q4, 2025 Results on Dec 11, 2025Covalon Technologies Ltd. announced that they will report Q4, 2025 results Pre-Market on Dec 11, 2025
공시 • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).
공시 • Sep 26Covalon Technologies Ltd. Presents Evidence-Backed Innovations Making A Difference for Critically Ill Children At AphonCovalon Technologies Ltd. presented evidence-backed innovations making a difference for critically ill Children At Aphon. The company announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference, September 25-27, 2025 in Providence, Rhode Island. The annual conference, attended by more than 800 nurse leaders from across the United States and around the world, is recognized as the premier educational experience for pediatric hematology/oncology nurses, bringing together clinicians and industry experts to advance knowledge, share research, and improve patient outcomes. Last week, the Journal of the Association for Vascular Access (JAVA) published peer-reviewed data from the Children's Hospital at Montefiore describing how the hospital's experience with VALGuard®? Line Guard was associated with positive outcomes, including a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024, and a sustained period of zero CLABSI's (Central Line Associated Blood Stream Infections) in the Pediatric Critical Care Unit. The publication provides peer-reviewed evidence on VALGuard®? and highlight its role in protecting vulnerable pediatric patients. In addition, new economic findings from a U.S. hospital study demonstrated that CovaClear®? silicone dressing, used as a cover for primary dressings, greatly helped reduce unplanned dressing changes caused by soiling, leaks, or contamination. Avoiding unplanned dressing changes translates into measurable cost savings for hospitals and reduced workload for nurses, while preserving skin integrity for patients who already face intensive therapies. These findings underscore the dual impact of Covalon's portfolio which is designed to improve patient outcomes while creating measurable efficiencies for hospitals seeking to optimize both quality of care and economic performance. At APHON, Covalon will showcase the breadth of its vascular access portfolio, including: VALGuard®? Line Guard - A transparent, single-use barrier designed to cover and protect IV line connections and catheter hubs from external contaminants, including body fluids and secretions that can lead to infection. VALGuard®? incorporates a unique quick-release pull strip that enables fast access to the line for clinicians. CovaClear®? Dressings - A family of versatile gentle-to-skin silicone dressings that can be used as a primary IV securement dressing or as a protective cover over existing primary dressings. By helping reduce unplanned primary IV dressing changes caused by soiled, fluid leaks, or external contamination, CovaClear®? helps customers save money on wasted supplies, reduce nursing workload, and supports efforts to preserve patient skin integrity. IV Clear®? Dressings - Afamily of transparent IV securement dressings that combine gentle-to-skin silicone adhesive technology with edge-to-edge coverage of chlorhexidine and silver for antimicrobial protection. IV Clear®? provides complete transparency to the insertion site, supporting routine assessment and better line management. The company's solutions are designed not only to support better outcomes for patients but also to provide hospitals with measurable savings and long-term value.
공시 • Sep 24Covalon Technologies Ltd. Announces Board ChangesCovalon Technologies Ltd. announced that Mr. Abe Schwartz has been elected Chair of the Board of the Company. Mr. Schwartz succeeds Mr. Amir Boloor, who has decided to step down as a director and Executive Chair of Covalon with effect September 23, 2025. Mr. Schwartz, a member of the Covalon Board since 2008, has previously served as Covalon Board Chair from 2012 until 2020. He has been a successful Healthcare and I.T. industry entrepreneur, CEO and investor over the past 50 years and is Covalon’s largest shareholder.
공시 • Aug 14Covalon Technologies Ltd. to Report Q3, 2025 Results on Aug 21, 2025Covalon Technologies Ltd. announced that they will report Q3, 2025 results Pre-Market on Aug 21, 2025
공시 • May 27Covalon Technologies Ltd. Announces New Clinical Research Evaluating Vascular Access Line GuardCovalon Technologies Ltd. announced that exciting results from a clinical study evaluating the use of its VALGuard Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall - September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world.
공시 • May 21Covalon Technologies Ltd. to Report Q2, 2025 Results on May 28, 2025Covalon Technologies Ltd. announced that they will report Q2, 2025 results Pre-Market on May 28, 2025
공시 • Feb 14Covalon Technologies Ltd. to Report Q1, 2025 Results on Feb 21, 2025Covalon Technologies Ltd. announced that they will report Q1, 2025 results Pre-Market on Feb 21, 2025
공시 • Jan 06Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025.
공시 • Dec 19Covalon Technologies Ltd. to Report Q4, 2024 Results on Jan 07, 2025Covalon Technologies Ltd. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Jan 07, 2025
공시 • Aug 14Covalon Technologies Ltd. to Report Q3, 2024 Results on Aug 21, 2024Covalon Technologies Ltd. announced that they will report Q3, 2024 results Pre-Market on Aug 21, 2024
공시 • May 24Covalon Technologies Ltd. to Report Q2, 2024 Results on May 29, 2024Covalon Technologies Ltd. announced that they will report Q2, 2024 results Pre-Market on May 29, 2024
공시 • Jan 26+ 1 more updateCovalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - OperationsCovalon Technologies Ltd. announced that Ms. Kim Crooks has rejoined Covalon as the Senior Vice President - Operations. In this new role, Ms. Crooks is responsible for overseeing the direction, planning, and execution of Manufacturing, Quality Assurance and Quality Control, Regulatory Affairs, and Human Resources. Ms. Crooks was previously Vice President of Operations at Covalon from 2012 to 2022.
공시 • Dec 21Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024.
공시 • Oct 12Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in ChicagoCovalon Technologies Ltd. announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference. Scheduled from October 12 to October 14, 2023, in Chicago, this conference is the largest conference for nurse professionals. All attendees are invited to booth 1835 at the McCormick Place Convention Center, where they can experience first-hand, innovative compassionate care solutions designed to elevate patient care standards and nursing excellence. Covalon's patented infection prevention and wound care products include: VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.
공시 • Sep 28Covalon Technologies Ltd. Announces Chief Executive Officer ChangesCovalon Technologies Ltd. appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer, effective immediately following the departure of Brian Pedlar. The Board has commenced a search for a permanent CEO. Mr. Boloor succeeds Brian Pedlar, who will remain on Covalon’s Board of Directors.
공시 • Sep 27Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent DirectorCovalon Technologies Ltd. appointed Joseph Cordiano to serve as lead independent director.
공시 • Aug 15Covalon Technologies Ltd. to Report Q3, 2023 Results on Aug 16, 2023Covalon Technologies Ltd. announced that they will report Q3, 2023 results Pre-Market on Aug 16, 2023
공시 • May 24Covalon Technologies Ltd. to Report Q2, 2023 Results on May 25, 2023Covalon Technologies Ltd. announced that they will report Q2, 2023 results Pre-Market on May 25, 2023
공시 • Feb 18Covalon Technologies Ltd. to Report Q1, 2023 Results on Feb 23, 2023Covalon Technologies Ltd. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 23, 2023
공시 • Jan 24Covalon Technologies Ltd. to Report Q4, 2022 Results on Jan 25, 2023Covalon Technologies Ltd. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 25, 2023